- TRADE NAME: Imlygic (Amgen)
- INDICATIONS: Unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
- SYNONYM: T-VEC
- CLASS: Oncolytic virus immunotherapy
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 10/27/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Contraception advised to prevent pregnancy during treatment
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of talimogene laherparepvec in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
